Circulating concentrations of vitamin D in relation to pancreatic cancer risk in European populations

• Type of Material: Article
• Authors: Franzel J.B. van Duijnhoven, National Institute for Public Health and the Environment (RIVM); Mazda Jenab, International Agency for Research on Cancer (IARC‐WHO); Kristian Hveem, Norwegian University of Science and Technology (NTNU); Peter D. Siersema, University Medical Center Utrecht; Veronika Fedirko, Emory University; Eric J. Duell, L'Hospitalet de Llobregat; Ellen Kampman, Wageningen University & Research; Anouk Halfweeg, Wageningen University & Research; Henk J. van Kranen, National Institute for Public Health and the Environment (RIVM); Jody M.W. van den Ouweland, Canisius Wilhelmina Hospital; Elisabete Weiderpass, University of Tromsø; Neil Murphy, International Agency for Research on Cancer (IARC‐WHO); Arnulf Langhammer, Norwegian University of Science and Technology; Eivind Ness-Jensen, Norwegian University of Science and Technology; Anja Olsen, Danish Cancer Society Research Center; Anne Tjonneland, Danish Cancer Society Research Center; Kim Overvad, Aarhus University; Claire Cadeau, Université Paris‐Sud; Marina Kvaskoff, Université Paris‐Sud; Marie-Christine Boutron-Ruault, Université Paris‐Sud; Verena A. Katzke, German Cancer Research Center (DKFZ); Tilman Kuehn, German Cancer Research Center (DKFZ); Heiner Boeing, German Institute for Human Nutrition Potsdam‐Rehbrücke; Antonia Trichopoulou, Hellenic Health Foundation; Anastasia Kotanidou, Hellenic Health Foundation; Maria Kritikou, Hellenic Health Foundation; Domenico Palli, Cancer Research and Prevention Institute—ISPO; Claudia Agnoli, Fondazione IRCCS Istituto Nazionale dei Tumori; Rosario Tumino, “Civic ‐ M.P.Arezzo” Hospital; Salvatore Panico, Federico II university; Giuseppe Matullo, University of Turin; Petra Peeters, University Medical Center Utrecht; Magritt Brustad, University of Tromsø; Karina Standahl Olsen, University of Tromsø; Cristina Lasheras, Oviedo University; Mireia Obon-Santacana, L'Hospitalet de Llobregat; Maria-Jose Sanchez, Universidad de Granada; Miren Dorronsoro, Basque Regional Health Department; Maria-Dolores Chirlaque, CIBER de Epidemiología y Salud Pública (CIBERESP); Aurelio Barricarte, CIBER de Epidemiología y Salud Pública (CIBERESP); Jonas Manjer, Lund University; Martin Almquist, Skane University Hospital; Frida Renstrom, Lund University; Weimin Ye, Karolinska Institutet; Nick Wareham, University of Cambridge; Kay-Tee Khaw, University of Cambridge; Kathryn E. Bradbury, University of Oxford; Heinz Freisling, International Agency for Research on Cancer (IARC‐WHO); Dagfinn Aune, Imperial College London; Teresa Norat, Imperial College London; Elio Riboli, Imperial College London; H. B(as) Bueno-de-Mesquita, National Institute for Public Health and the Environment (RIVM)
• Language: English
• Date: 2018-03-15
• Publisher: Wiley
• Publication Version: Final Published Version
• Copyright Statement: © 2017 The Authors International Journal of Cancer published by John Wiley & Sons Ltd on behalf of UICC
• License: Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International
• Final Published Version (URL): http://dx.doi.org/10.1002/ijc.31146
• Title of Journal or Parent Work: International Journal of Cancer
• ISSN: 0020-7136
• Volume: 142
• Issue: 6
• Start Page: 1189
• End Page: 1201
• Grant/Funding Information: The Nord‐Trøndelag Health Study (The HUNT Study) is a collaboration between HUNT Research Centre (Faculty of Medicine, Norwegian University of Science and Technology NTNU), Nord‐Trøndelag County Council, Central Norway Health Authority, and the Norwegian Institute of Public Health.; The national cohorts are supported by Danish Cancer Society (Denmark); Ligue Contre le Cancer, Institut Gustave Roussy, Mutuelle Générale de l'Education Nationale, Institut National de la Santé et de la Recherche Médicale (INSERM) (France); German Cancer Aid, German Cancer Research Center (DKFZ), Federal Ministry of Education and Research (BMBF), Deutsche Krebshilfe, Deutsches Krebsforschungszentrum and Federal Ministry of Education and Research (Germany); the Hellenic Health Foundation (Greece); Associazione Italiana per la Ricerca sul Cancro‐AIRC‐Italy and National Research Council (Italy); Dutch Ministry of Public Health, Welfare and Sports (VWS), Netherlands Cancer Registry (NKR), LK Research Funds, Dutch Prevention Funds, Dutch ZON (Zorg Onderzoek Nederland), World Cancer Research Fund (WCRF), Statistics Netherlands (The Netherlands); ERC‐2009‐AdG 232997 and Nordforsk, Nordic Centre of Excellence programme on Food, Nutrition and Health (Norway); Health Research Fund (FIS), PI13/00061 (to Granada), PI13/01162 (to EPIC‐Murcia), Regional Government of Asturias, Basque Country, Murcia and Navarra, ISCIII RETIC (RD06/0020) (Spain); Swedish Cancer Society, Swedish Research Council and County Councils of Skåne and Västerbotten (Sweden); Cancer Research UK (14136 [to EPIC‐Norfolk]; C570/A16491 and C8221/A19170 [to EPIC‐Oxford]), Medical Research Council (UK) (1000143 [to EPIC‐Norfolk], MR/M012190/1 [to EPIC‐Oxford]).; This work was financially supported by World Cancer Research Fund International and Wereld Kanker Onderzoek Fonds (WKOF) with grant 2010/252 and by the Dutch Cancer Society with grant UW 2010–4872.; The coordination of EPIC is financially supported by the European Commission (DG‐SANCO) and the International Agency for Research on Cancer.
• Keywords: ULTRAVIOLET-B IRRADIANCE; Oncology; LATITUDE; Science & Technology; Life Sciences & Biomedicine; D ANALOGS; PROLIFERATION; REGRESSION; 25-HYDROXYVITAMIN D; vitamin D; cancer epidemiology; nested case-control study; pancreatic cancer; VIVO; FORTIFIED MILK; GENOME-WIDE ASSOCIATION; CELLS IN-VITRO
• Research Categories: Health Sciences, Public Health; Health Sciences, Epidemiology

Abstract

Evidence from in vivo, in vitro and ecological studies are suggestive of a protective effect of vitamin D against pancreatic cancer (PC). However, this has not been confirmed by analytical epidemiological studies. We aimed to examine the association between pre-diagnostic circulating vitamin D concentrations and PC incidence in European populations. We conducted a pooled nested case-control study within the European Prospective Investigation into Cancer and Nutrition (EPIC) and the Nord-Trøndelag Health Study's second survey (HUNT2) cohorts. In total, 738 primary incident PC cases (EPIC n = 626; HUNT2 n = 112; median follow-up = 6.9 years) were matched to 738 controls. Vitamin D [25(OH)D 2 and 25(OH)D 3 combined] concentrations were determined using isotope-dilution liquid chromatography-tandem mass spectrometry. Conditional logistic regression models with adjustments for body mass index and smoking habits were used to estimate incidence rate ratios (IRRs) and 95% confidence intervals (95%CI). Compared with a reference category of > 50 to 75 nmol/L vitamin D, the IRRs (95% CIs) were 0.71 (0.42–1.20); 0.94 (0.72–1.22); 1.12 (0.82–1.53) and 1.26 (0.79–2.01) for clinically pre-defined categories of ≤25; > 25 to 50; > 75 to 100; and > 100 nmol/L vitamin D, respectively (p for trend = 0.09). Corresponding analyses by quintiles of season-standardized vitamin D concentrations also did not reveal associations with PC risk (p for trend = 0.23). Although these findings among participants from the largest combination of European cohort studies to date show increasing effect estimates of PC risk with increasing pre-diagnostic concentrations of vitamin D, they are not statistically significant.